Dutch Biologic Monitor: Fatigue Among Biologic Recipients Across a Range of Immune-Mediated Inflammatory Diseases

Source: Clinical Impact of New Rheumatoid Arthritis Findings From EULAR 2020*
Download Slideset
June 3-6, 2020; Virtual Meeting
Overall, 7% of adults self-reported biologic-associated fatigue. Compared with patients not reporting fatigue, they were younger and more frequently smoked, were more likely to have Crohn disease, and used infliximab, rituximab, or vedolizumab.
Format: Microsoft PowerPoint (.ppt)
File Size: 205 KB
Released: August 13, 2020

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
AbbVie Inc.
Gilead Sciences, Inc.

Related Content

Downloadable slide set featuring expert guidance on therapeutic drug monitoring in IBD

Marla Dubinsky, MD Bruce E. Sands, MD, MS Released: January 19, 2022

Expert insights from ACR 2021, including the most important data to clinical practice on the management of axPsA and axSpA, from Clinical Care Options (CCO)

Philip Mease, MD, MACR Released: December 23, 2021

Expert insights from ACR 2021, including the most important data for clinical practice on the management of axSpA and axPsA, from Clinical Care Options (CCO)

Atul Deodhar, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Released: December 22, 2021 Expired: December 21, 2022

From Clinical Care Options (CCO), new data in managing axial psoriatic arthritis and axial spondyloarthritis from EULAR 2021

Atul Deodhar, MD Philip Mease, MD, MACR Physicians: maximum of 0.5 AMA PRA Category 1 Credits™ Released: September 2, 2021 Expired: September 1, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings